SSG XI

Titel	Palliative oral trofosfamide in the treatment of metastatic or locally advanced soft-tissue sarcoma
Akronym	SSG XI
Typ av studie	Non-randomized multicentric study
Sponsor	Scandinavian Sarcoma Group (SSG)
Inklusionskriterier	Patients with histologically confirmed soft-tissue sarcoma not treatable by local treatment modalities Patients unsuitable for aggressive chemotherapy Patient receiving first-line systemic treatment for soft-tissue sarcoma Evaluable or measurable metastases: WHO performance score 0-3 WBC count >3.0 x 109/L, patelet count >100 000/L
Studiedesign	Trofosfamide: 150 mg/day
Endpoint(s)	Progression-free survival
Rekryteringsperiod	1994-1996
Antal inkluderade patienter	40
Publikationer

Tillbaka till Kliniska prövningar

Uppdaterad: 2008 06 25